Just the beginning: Novel functions for angiotensin-converting enzymes

Current Biology

Volumn 12, Issue 21, 2002, Pages

  Eriksson, Urs ^a   Danilczyk, Ursula ^a   Penninger, Josef M ^b  

^a INSTITUTE OF MOLECULAR BIOTECHNOLOGY   (Austria)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE;

AMINO ACID SEQUENCE; ANIMAL; CHEMISTRY; METABOLISM; MOUSE; REVIEW;

AMINO ACID SEQUENCE; ANIMALS; MICE; PEPTIDYL-DIPEPTIDASE A;

ANIMALIA; MAMMALIA;

EID: 0037195251     PISSN: 09609822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9822(02)01255-1     Document Type: Review

References (72)

1. Inagami, T. (1994). The renin-angiotensin system. Essays Biochem. 28, 147-164.
2. Weinberg, M.S., Weinberg, A.J. and Zappe, D.H. (2000). Effectively targeting the renin-angiotensin-aldosterone system in cardiovascular and renal disease: Rationale for using angiotensin II receptor blockers in combination with angiotensin-converting enzyme inhibitors. J Renin Angiotensin Aldosterone Syst. 1, 217-233.
3. Skeggs, L.T., Dorer, F.E., Levine, M., Lentz, K.E. and Kahn, J.R. (1980). The biochemistry of the renin-angiotensin system. Adv. Exp. Med. Biol. 130, 1-27.
4. Turner, A.J. and Hooper, N.M. (2002). The angiotensin-converting enzyme gene family: Genomics and pharmacology. Trends Pharmacol. Sci. 23, 177-183.
5. Tipnis, S.R., Hooper, N.M., Hyde, R., Karran, E., Christie, G. and Turner, A.J. (2000). A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J. Biol. Chem. 275, 33238-33243.
6. Donoghue, M., Hsieh, F., Baronas, E., Godbout, K., Gosselin, M., Stagliano, N., Donovan, M., Woolf, B., Robison, K., Jeyaseelan, R. et al. (2000). A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ. Res. 87, E1-E9.
7. Crackower, M.A., Sarao, R., Oudit, G.Y., Yagil, C., Kozieradzki, I., Scanga, S.E., Oliveira-Dos-Santos, A.J., Da Costa, J., Zhang, L., Pei, Y. et al. (2002). Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417, 822-828.
8. Wei, C.C., Tian, B., Perry, G., Meng, Q.C., Chen, Y.F., Oparil, S. and Dell'ltalia, L.J. (2002). Differential ANG II generation in plasma and tissue of mice with decreased expression of the ACE gene. Am. J. Physiol. Heart Circ. Physiol. 282, H2254-H2258.
9. Dinh, D.T. (2001). Angiotensin receptors: Distribution, signaling and function. Clin. Science 100, 481-492.
10. Meffert, S., Stoll, M., Steckelings, U.M., Bottari, S.P. and Unger, T. (1996). The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol. Cell. Endocrinol. 22, 59-67.
11. Brede, M. and Hein, L. (2001). Transgenic mouse models of angiotensin receptor subtype function in the cardiovascular system. Regul. Pept. 96, 125-132.
12. Ito, M., Oliverio, M.I., Mannon, P.J., Best, C.F., Maeda, N., Smithies, O. and Coffman, T.M. (1995). Regulation of blood pressure by the type 1A angiotensin II receptor gene. Proc. Natl. Acad. Sci. U.S.A. 92, 3521-3525.
13. Wright, J.W. and Harding, J.W. (1997). Important role for angiotensin III and IV in the brain renin-angiotensin system. Brain Res. Rev. 25, 96-124.
14. Allred, A.J., Diz, D.I., Ferrario, C.M. and Chappell, M.C. (2000). Pathways for angiotensin-(1-7) metabolism in pulmonary and renal tissues. Am. J. Physiol. Renal Physiol. 279, F841-F850.
15. Brosnihan, K.B., Li, P., Tallant, E.A. and Ferrario, C.M. (1998). Angiotensin-(1-7): A novel vasodilator of the coronary circulation. Biol. Res. 31, 227-234.
16. Jackman, H.L., Massad, M.G., Sekosan, M., Tan, F., Brovkovych, V., Marcic, B.M. and Erdos, E.G. (2002). Angiotensin 1-9 and 1-7 release in human heart: Role of cathepsin A. Hypertension 39, 976-981.
17. Iyer, S.N., Averill, D.B., Chappell, M.C., Yamada, K., Allred, A.J. and Ferrario, C.M. (2000). Contribution of angiotensin-(1-7) to blood pressure regulation in salt-depleted hypertensive rats. Hypertension 36, 417-422.
18. Moeller, I., Chai, S.Y., Oldfield, B.J., McKinley, M.J., Casley, D. and Mendelsohn, F.A. (1995). Localization of angiotensin IV binding sites to motor and sensory neurons in the sheep spinal cord and hindbrain. Localization of angiotensin IV binding sites to motor and sensory neurons in the sheep spinal cord and hindbrain. Brain Res. 701, 301-306.
19. Albiston, A.L., McDowall, S.G., Matsacos, D., Sim, P., Clune, E., Mustafa, T., Lee, J., Mendelsohn, F.A., Simpson, R.J., Connolly, L.M. et al. (2001). Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J. Biol. Chem. 276, 48623-48626.
20. Skeggs, L.T. (1956). The preparation and function of the hypertensin converting enzyme. J. Exp. Med. 103, 295-299.
21. Soubrier, F., Alhenc-Gelas, F., Hubert, C., Allegrini, J., John, M., Tregear, G. and Corvol, P. (1988). Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc. Natl. Acad. Sci. U.S.A. 85, 9386-9390.
22. Krege, J.H., John, S.W., Langenbach, L.L., Hodgin, J.B., Hagaman, J.R., Bachman, E.S., Jennette, J.C., O'Brien, D.A., Smithies, O. (1995). Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 375, 146-148.
23. Esther, C.R., Jr., Howard, T.E., Marino, E.M., Goddard, J.M., Capecchi, M.R. and Bernstein, K.E. (1997). Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology and reduced male fertility. Lab. Invest. 74, 953-965.
24. Sugaya, T., Nishimatsu, S., Tanimoto, K., Takimoto, E., Yamagishi, T., Imamura, K., Goto, S., Imaizumi, K., Hisada, Y., Otsuka, A. et al. (1995). Angiotensin II type 1 a receptor-deficient mice with hypotension and hyperreninemia. J. Biol. Chem. 270, 18719-18722.
25. Tschope, C., Schultheiss, H.P. and Walther, T. (2002). Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: Role of ACE inhibition and AT1 receptor blockade. J. Cardiovasc. Pharmacol. 39, 478-487.
26. Yang, H.Y.T. (1970). A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochem. Biophys. Acta 214, 374-376.
27. Skidgel, R.A. and Erdoes, E.G. (1985). Novel activity of human angiotensin I converting enzyme: Release of the NH2 and COOH terminal tripeptides from the luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. U.S.A. 82, 1025-1029.
28. Cushman, D.W. and Ondetto, M.A. (1999). Design of angiotensin-converting enzyme inhibitors. Nat. Med. 5, 1110-1112.
29. Garg, R. and Yusuf, S. (1995). Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. J. Am. Med. Assoc. 273, 1450-1456.
30. Zhang, H., Wada, J., Hida, K., Tsuchiyama, Y., Hiragushi, K., Shikata, K., Wang, H., Lin, S., Kanwar, Y.S. and Makina, H. (2001). Collectrin, a collecting duct-specific transmembrane glycoprotein, is a novel homolog of ACE2 and is developmentally regulated in embryonic kidneys. J. Biol. Chem. 276, 17132-17139.
31. Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J., Godbout, K., Parsons, T., Baronas, E., Hsieh, F. et al. (2002). Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J. Biol. Chem. 277, 14838-14843.
32. Ren, Y., Garvin, J.L. and Carretero, O.A. (2002). Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension 39, 799-802.
33. Lemos, V.S., Cortes, S.F., Silva, D.M., Campagnole-Santos, M.J. and Santos, R.A. (2002). Angiotensin 1-7 is involved in the endothelium dependent modulation of phenylephrine-induced contraction in the aorta of mRen-2 transgenic rats. Br. J. Pharmacol. 135, 1743-1748.
34. Marceau, F., Hess, J.F. and Bachvarov, D.R. (1998). The B1 receptors for kinins. Pharmacol. Rev. 50, 357-386.
35. Duka, I., Kintsurashvili, E., Gavras, I., Johns, C., Bresnahan, M. and Gavras, H. (2001). Vasoactive potential of the B(1) bradykinin receptor in normotension and hypertension. Circ. Res. 88, 275-281.
36. Ignjatovic, T., Tan, F., Brovkovych, V., Skidgel, R.A. and Erdos, E.G. (2002). Novel mode of action of angiotensin I converting enzyme inhibitors: Direct activation of bradykinin B1 receptor. J. Biol. Chem. 277, 16847-16852.
37. Lee, D.K., Cheng, R., Nguyen, T., Fan, T., Kariyawasam, A.P., Liu, Y., Osmond, D.H., George, S.R. and O'Dowd, B.F. (2000). Characterization of apelin, the ligand for the APJ receptor. J. Neurochem. 74, 34-41.
38. Tatemoto, K., Hosoya, M., Habata, Y., Fujii, R., Kakegawa, T., Zou, M.X., Kawamata, Y., Fukusumi, S., Hinuma, S., Kitada, C. et al. (1998). Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem. Biophys. Res. Commun. 251, 471-476.
39. Hosoya, M., Kawamata, Y., Fukusumi, S., Fujii, R., Habata, Y., Hinuma, S., Kitada, C., Honda, S., Kurokawa, T., Onda, H. et al. (2000). Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J. Biol. Chem. 275, 21061-21067.
40. Kawamata, Y., Habata, Y., Fukusumi, S., Hosoya, M., Fujii, R., Hinuma, S., Nishizawa, N., Kitada, C., Onda, H., Nishimura, O. et al. (2001). Molecular properties of apelin: Tissue distribution and receptor binding. Biochim. Biophys. Acta 1538, 162-171.
41. Katugampola, S.D., Maguire, J.J., Kuc, R.E., Wiley, K.E. and Davenport, A.P. (2002). Discovery of recently adopted orphan receptors for apelin, urotensin II and ghrelin identified using novel radioligands and functional role in the human cardiovascular system. Can. J. Physiol. Pharmacol. 80, 369-374.
42. Tatemoto, K., Takayama, K., Zou, M.X., Kumaki, I., Zhang, W., Kumano, K. and Fujimiya, M. (2001). The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul. Pept. 99, 87-92.
43. 2+ release from an intracellular pool in myocytes and neurons. Circ. Res. 70, 66-81.
44. Wenzlaff, H., Stein, B. and Teschemacher, H. (1998). Diminution of contractile response by kappa-opioid receptor agonists in isolated rat ventricular cardiomyocytes is mediated via a pertussis toxin-sensitive G protein. Naunyn Schmiedebergs Arch. Pharmacol. 358, 360-366.
45. Pugsley, M.K. (2002). The diverse molecular mechanisms responsible for the actions of opioids on the cardiovascular system. Pharmacol. Ther. 93, 51-75.
46. Carretero, O.A. and Oparil, S. (2000). Essential hypertension. Part I: Definition and etiology. Circulation 101, 329-335.
47. Kurokawa, K. (1998). Tubuloglomerular feedback: Its physiological and pathophysiological significance. Kidney Int. Suppl. 67, S71-S74.
48. Kovacs, G., Peti-Peterdi, J., Rosivall, L. and Bell, P.D. (2002). Angiotensin II directly stimulates macula densa Na-2Cl-K cotransport via apical AT(1) receptors. Am. J. Physiol. Renal Physiol. 282, F301-F306.
49. Fardella, C.E., Mosso, L., Gomez-Sanchez, C., Cortes, P., Soto, J., Gomez, L., Pinto, M., Huete, A., Oestreicher, E., Foradori, A. et al. (2000). Primary hyperaldosteronism in essential hypertensives: Prevalence, biochemical profile and molecular biology. J. Clin. Endocrinol. Metab. 85, 1863-1867.
50. Stoll, M., Kwitek-Black, A.E., Cowley, A.W., Jr., Harris, E.L., Harrap, S.B., Krieger, J.E., Printz, M.P., Provoost, A.P., Sassard, J. and Jacob, H.J. (2000). New target regions for human hypertension via comparative genomics. Genome Res. 10, 473-482.
51. Korstanje, R. and Paigen, B. (2002). From QTL to gene: The harvest begins. Nat. Genet. 31, 235-236.
52. Niimura, F., Labosky, P.A., Kakuchi, J., Okubo, S., Yoshida, H., Oikawa, T., Ichiki, T., Naftilan, A.J., Fogo, A., Inagami, T. et al. (1995). Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J. Clin. Invest. 96, 2947-2954
53. Oliverio, M.I., Kim, H.S., Ito, M., Le, T., Audoly, L., Best, C.F., Hiller, S., Kluckman, K., Maeda, N., Smithies, O. et al. (1998). Reduced growth, abnormal kidney structure and type 2 (AT2) angiotensin receptor-mediated blood pressure regulation in mice lacking both AT1A and AT1B receptors for angiotensin II. Proc. Natl. Acad. Sci. U.S.A. 95, 15496-15501.
54. Li, P., Chappell, M.C., Ferrario, C.M., Brosnihan, K.B. (1997) Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 29, 394-400.
55. Stoll, M. and Jacob, H.J. (2001). Genetic rat models of hypertension: Relationship to human hypertension. Curr. Hypertens. 3, 157-164.
56. Murphy, A.M., Kogler, H., Georgakopoulos, D., McDonough, J.L., Kass, D.A., Van Eyk, J.E. and Marban, E. (2000). Transgenic mouse model of stunned myocardium. Science 287, 488-491.
57. Heusch, G. (1998). Hibernating myocardium. Physiol. Rev. 78, 1055-1085.
58. Kloner, R.A., Bolli, R., Marban, E., Reinlib, L. and Braunwald, E. (1998). Medical and cellular implications of stunning, hibernation and preconditioning: An NHLBI workshop. Circulation 97, 1848-1867.
59. Deindl, E. and Scharper, W. (1998). Gene expression after short periods of coronary occlusion. Mol. Cell. Biochem. 196, 43-51.
60. Kloner, R.A. and Jennings, R.B. (2001). Consequences of brief ischemia: Stunning, preconditioning and their clinical implications: Part 1. Circulation 104, 2981-2989.
61. Cai, H. and Harrison, D.G. (2000). Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circ. Res. 87, 840-844.
62. Griendling, K.K. and Ushio-Fukai, M. (1997). NADH/NADPH oxidase and vascular function. Trends Cardiovasc. Med. 7, 301-307.
63. Richard, D.E., Berra, E. and Pouyssegur, J. (2000). Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. J. Biol. Chem. 275, 26765-26771.
64. Nickenig, G. and Harrison, D.G. (2002). The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part I: Oxidative stress and atherogenesis. Circulation 105, 393-396.
65. Loot, A.E., Roks, A.J., Henning, R.H., Tio, R.A., Suurmeijer, A.J., Boomsma, F. and van Gilst, W.H. (2002). Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105, 1548-1550.
66. Regula, K.M., Ens, K. and Kirshenbaum, L. A. (2002). Inducible expression of BNIP3 provokes mitochrondrial defects and hypoxia-mediated cell death of ventricular myocytes. Circ. Res. 91, 226-231.
67. Sowter, H.M., Ratcliffe, P.J., Watson, P., Greenberg, A.H. and Harris, A.L. (2001). HIF-1-dependent regulation of hypoxic induction of the cell death factors BNIP3 and NIX in human tumors. Cancer Res. 61, 6669-6673.
68. Quignard, J.F., Mironneau, J., Carricaburu, V., Fournier, B., Babich, A., Nurnberg, B., Mironneau, C. and Macrez, N. (2001). Phosphoinositide 3-kinase gamma mediates angiotensin II-induced stimulation of L-type calcium channels in vascular myocytes. J. Biol. Chem. 276, 32545-32551.
69. Saward, L. and Zahradka, P. (1997). Angiotensin II activates phosphatidylinositol 3-kinase in vascular smooth muscle cells. Circ. Res. 81, 249-257.
70. Wort, S.J. and Evans, T.W. (1999). The role of the endothelium in modulating vascular control in sepsis and related conditions. Br. Med. Bull. 55, 30-48.
71. Ammann, P., Fehr, T., Minder, E.I., Gunter, C. and Bertel, O. (2001). Elevation of troponin I in sepsis and septic shock. Intensive Care Med. 6, 965-969.
72. Wu, A.H. (2001). Increased troponin in patients with sepsis and septic shock: Myocardial necrosis or reversible myocardial depression? Intensive Care Med. 6, 959-961.